摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(dimethylamino)-1-(3-iodo-1-ethyl-1H-pyrazol-4-yl)prop-2-en-1-one | 1269440-52-9

中文名称
——
中文别名
——
英文名称
3-(dimethylamino)-1-(3-iodo-1-ethyl-1H-pyrazol-4-yl)prop-2-en-1-one
英文别名
3-(Dimethylamino)-1-(1-ethyl-3-iodopyrazol-4-yl)prop-2-en-1-one
3-(dimethylamino)-1-(3-iodo-1-ethyl-1H-pyrazol-4-yl)prop-2-en-1-one化学式
CAS
1269440-52-9
化学式
C10H14IN3O
mdl
——
分子量
319.145
InChiKey
JJHQDSMGGUVBJP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    38.1
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • [EN] PYRIMIDINE INHIBITORS OF KINASE ACTIVITY<br/>[FR] INHIBITEURS PYRIMIDINES DE L'ACTIVITÉ KINASE
    申请人:ABBOTT LAB
    公开号:WO2010138575A1
    公开(公告)日:2010-12-02
    Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, L1, R2, R3, n, p, Ar1, and Ar2 are defined in the description. Methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR are also disclosed.
    本文描述了式(I)的化合物或其药用可接受的盐或溶剂化合物,其中G1、L1、R2、R3、n、p、Ar1和Ar2在描述中有定义。还公开了制备所述化合物的方法,以及包含所述化合物的用于抑制IGF-IR等激酶的组合物。
  • [EN] COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
    申请人:IRM LLC
    公开号:WO2011025927A1
    公开(公告)日:2011-03-03
    The invention provides a novel class of compounds of formula 1, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    这项发明提供了一类新型的化合物,其化学式为1,包括这些化合物的药物组合物以及使用这些化合物来治疗或预防与异常或失调的激酶活性相关的疾病或障碍的方法,特别是涉及B-Raf异常激活的疾病或障碍。
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    申请人:Huang Shenlin
    公开号:US20110306625A1
    公开(公告)日:2011-12-15
    The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    本发明提供了一类新型化合物,包括这些化合物的药物组成物,以及使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或疾病的方法,特别是涉及B-Raf异常活化的疾病或疾病的方法。
  • PYRIMIDINE INHIBITORS OF KINASE ACTIVITY
    申请人:Clark Richard F.
    公开号:US20100305118A1
    公开(公告)日:2010-12-02
    Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G 1 , L 1 , R 2 , R 3 , n, p, Ar 1 , and Ar 2 are defined in the description. Methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-1R are also disclosed.
    本文描述了公式(I)的化合物或其药学上可接受的盐或溶剂,其中G1、L1、R2、R3、n、p、Ar1和Ar2在描述中有定义。还公开了制备上述化合物的方法和包含该化合物的组合物,该组合物对于抑制IGF-1R等激酶是有用的。
  • Compounds and compositions as protein kinase inhibitors
    申请人:Array BioPharma, Inc.
    公开号:US10005761B2
    公开(公告)日:2018-06-26
    The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    本发明提供了一类新型化合物、包含此类化合物的药物组合物以及使用此类化合物治疗或预防与激酶活性异常或失调有关的疾病或紊乱的方法,特别是涉及 B-Raf 异常活化的疾病或紊乱。
查看更多